Original Article
A Controlled Trial of Intravaginal Estriol in Postmenopausal Women with Recurrent Urinary Tract Infections
N Engl J Med 1993; 329:753-756September 9, 1993
- Abstract
Background
Recurrent urinary tract infections are a problem for many postmenopausal women. Estrogen replacement restores atrophic mucosa, lowers vaginal pH, and may prevent urinary tract infections.
Methods
We enrolled 93 postmenopausal women with a history of recurrent urinary tract infections in a randomized, double-blind, placebo-controlled trial of a topically applied intravaginal estriol cream. Midstream urine cultures were obtained at enrollment, monthly for eight months, and whenever urinary symptoms occurred. Vaginal cultures and pH measurements were obtained at entry and after one and eight months. The women were assigned to receive either estriol (n = 50) or placebo (n = 43), both administered intravaginally; 36 and 24, respectively, completed the eight months of follow-up.
Results
The incidence of urinary tract infection in the group given estriol was significantly reduced as compared with that in the group given placebo (0.5 vs. 5.9 episodes per patient-year, P<0.001). Survival analysis showed that more of the women in the estriol group than in the placebo group remained free of urinary tract infection (P<0.001). Lactobacilli were absent in all vaginal cultures before treatment and reappeared after one month in 22 of 36 estriol-treated women (61 percent) but in none of the 24 placebo recipients (P<0.001). With estriol the mean vaginal pH declined from 5.5 to 3.8 (P<0.001), whereas there was no significant change with placebo. The rate of vaginal colonization with Enterobacteriaceae fell from 67 percent to 31 percent in estriol recipients but was virtually unchanged (from 67 to 63 percent) in the placebo recipients (P<0.005). Side effects were minor, but caused 10 estriol recipients (28 percent) and 4 placebo recipients (17 percent) to discontinue treatment.
Conclusions
The intravaginal administration of estriol prevents recurrent urinary tract infections in postmenopausal women, probably by modifying the vaginal flora.
Media in This Article
Figure 1
Kaplan-Meier Analysis Showing the Cumulative Proportions of Women Remaining Free of Urinary Tract Infections in the Estriol and Placebo Groups (P<0.001 by the Log-Rank Test).Table 1
Characteristics of the Women in the Estriol and Placebo Groups.Article Activity
- Article
An estimated 10 to 15 percent of women over 60 years of age have frequent urinary tract infections1. Hormonally induced changes in the vaginal flora associated with menopause are thought to play an important part in the pathogenesis of urinary tract infections in older women. In premenopausal women, circulating estrogens encourage colonization of the vagina by lactobacilli, which produce lactic acid from glycogen and maintain a low vaginal pH that inhibits the growth of many uropathogens2,3. After menopause, however, the vaginal pH increases, lactobacilli disappear from the vaginal flora, and the vagina is predominantly colonized by Enterobacteriaceae, especially Escherichia coli. Such colonization presumably accounts in part for the increased susceptibility of these women to urinary tract infections4.
Previous studies by Parsons and Schmidt5 and Brandberg et al.6 suggested that estrogen replacement with either a topically applied vaginal cream or an orally administered agent restores the atrophic vaginal, urethral, and trigonal mucosa; lowers the vaginal pH; and may reduce the occurrence of urinary tract infections. However, the studies involved only a small number of women, they were not randomized or blinded, and neither had an untreated comparative group. We undertook this randomized, double-blind study to determine whether topically applied vaginal estriol cream was more effective than placebo cream in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections and to ascertain the effects of topical estrogen on the vaginal flora.
Methods
Patient Population and Recruitment
Postmenopausal women who had been referred to the Infectious Disease Clinic at Central Emek Hospital, Afula, Israel, with a history of three or more microbiologically confirmed symptomatic episodes of urinary tract infection during the previous year were included in the study. Patients with thromboembolic disorders, severe liver disease, estrogen-dependent tumors, anatomical lesions in the urogenital area, an indwelling urinary catheter, or a history of long-term use of antimicrobial agents for the prevention of urinary tract infections or for other reasons were excluded from the study, as were women receiving oral estrogen therapy.
After providing informed consent, all patients were evaluated clinically and gynecologically, and each provided a urine specimen to exclude current infection. After a negative culture result was obtained, patients were randomly assigned to one of two regimens: one group received 0.5 mg of estriol in vaginal cream to be used once each night for two weeks followed by twice-weekly applications for eight months, and the other group received a placebo cream to be used in the same manner.
Follow-up Schedule and Outcome Measurements
At study entry, the women received a tube of their assigned cream, a vaginal applicator, and a diary in which to record their use of the cream, the occurrence of side effects, symptoms of urinary tract infection, and the use of antibiotics. They visited the outpatient clinic monthly throughout the study. At each visit, the diary was reviewed so that we could evaluate treatment compliance.
Vaginal pH was measured and vaginal cultures were obtained at study entry and after one and eight months of treatment. Vaginal cultures were obtained by rolling a swab across the lateral vaginal wall just inside the introitus. The swab was promptly inoculated onto MacConkey agar to isolate aerobic gram-negative rods and onto fresh Rogosa agar to isolate lactobacilli. Midstream urine specimens were also obtained at study entry and at each monthly visit during the eight months of follow-up, or whenever symptoms of urinary tract infection appeared.
The diagnosis of symptomatic urinary tract infection was based on the presence of typical clinical symptoms (dysuria, frequency, urgency, and incontinence) in addition to laboratory evidence of pyuria (at least 8 leukocytes per cubic millimeter of unspun urine) and a midstream urine culture yielding ≥ 105 colony-forming units (CFU) per milliliter. In symptomatic patients with a positive culture without pyuria, a second urine sample was obtained with an indwelling catheter. Asymptomatic bacteriuria was considered to be present if the midstream urine culture yielded ≥ 105 CFU per milliliter without accompanying clinical symptoms. Women with asymptomatic bacteriuria were not treated with antibiotics unless symptoms developed. Symptomatic urinary tract infections were treated with a three-day regimen of either trimethoprim-sulfamethoxazole or ciprofloxacin.
Microbiologic Techniques
Midstream urine specimens were collected and cultured with the Uritest system (Hylab, Rehovot, Israel). All isolates were identified by standard procedures and tested for susceptibility to antimicrobial drugs by the Kirby-Bauer method. Lactobacillus was identified by the catalase reaction, beta-hemolysis on human bilayer Tween agar, and typical morphologic characteristics on Gram's staining. The vaginal pH was measured with pH indicator paper (Universal indicator, Merck Sharp & Dohme, West Point, Pa.) applied directly to the vaginal mucosa just inside the introitus.
Statistical Analysis
The chi-square test was used to compare dichotomous variables, and Student's t-test was used to compare continuous variables. The cumulative proportions of estrogen-treated women and placebo recipients who were free of bacteriuria in each month of the study were compared by Kaplan-Meier survival analysis and the log-rank test. The cumulative likelihood of remaining disease-free at four months and the 95 percent confidence intervals at four months were calculated with product-limit estimates. The annualized incidence rates in the two groups were compared by the Wilcoxon test.
Results
Comparison of the Study Groups
Ninety-three women participated in the study: 50 were randomly assigned to receive estriol cream, and 43 to receive placebo cream (Table 1Table 1
Characteristics of the Women in the Estriol and Placebo Groups.). The mean ages of the estriol-treated women (64.7 years; range, 52 to 81) and the placebo recipients (65.4 years; range, 51 to 79) were comparable, as was the number of urinary tract infections the women had had in the previous year (mean [±SE], 5.2 ±1.1 vs. 5.4 ±1.4). Thirty-six women given estriol and 24 women who received placebo completed the entire eight months of the study and were compliant with medication use. The following were reasons for early withdrawal from the study: side effects in 10 women in the estriol group and 4 in the placebo group; lack of compliance with follow-up in 3 and 5 women, respectively; death due to myocardial infarction in 1 estriol-treated patient; and failure to respond to topical prophylaxis necessitating systemic antimicrobial prophylaxis for recurrent infections in 10 women in the placebo group (Table 1).Rates of Infection in the Study Groups
The estrogen-treated women and the placebo recipients were followed for a total of 310 and 225 person-months, respectively (Table 2Table 2
Episodes of Infection in the Two Groups.). The annualized median incidence of urinary tract infections in the group given estrogen was significantly lower than the rate in the group given placebo (0.5 vs. 5.9 per patient-year, P<0.001 by the Wilcoxon test). Kaplan-Meier analysis showed that the cumulative proportion of patients remaining free of urinary tract infection was significantly higher in the group given estriol than in the group given placebo (P<0.001 by the log-rank test) (Figure 1Figure 1Kaplan-Meier Analysis Showing the Cumulative Proportions of Women Remaining Free of Urinary Tract Infections in the Estriol and Placebo Groups (P<0.001 by the Log-Rank Test).). After four months of treatment, the cumulative likelihood of remaining disease-free was 0.95 (95 percent confidence interval, 0.88 to 1.0) in the estrogen-treated women and 0.30 (95 percent confidence interval, 0.16 to 0.46) in the placebo recipients. The eight infected patients in the estriol group had 12 episodes of bacteriuria; 10 were symptomatic, and 2 were asymptomatic. The 27 infected patients in the placebo group had 111 episodes of bacteriuria; 103 were symptomatic, and 8 were asymptomatic (Table 2).The estrogen-treated patients used significantly fewer antibiotics for the treatment of urinary tract infections during the study. Thus, among the women followed for the entire eight months, the mean number of days of antibiotic use per patient was considerably lower in the women who received estrogen than in those who received placebo (6.9 ±1.1 vs. 32.0 ±7.8, P<0.001).
Alterations in Vaginal pH and Flora
At the beginning of the study, none of the women in either group had vaginal cultures that were positive for lactobacilli (Table 3Table 3
Alterations in Vaginal Flora and pH in the Two Groups.). In contrast, after one and eight months, lactobacilli were detected in the vaginas of 22 and 21, respectively, of the 36 estriol-treated patients who were seen at both visits but in none of the placebo recipients (P<0.001 for the comparison between groups at each time). On the other hand, the number of estriol-treated women with vaginal cultures positive for Enterobacteriaceae fell from 24 (67 percent) before therapy to 11 (31 percent) after one month of treatment and to 10 (28 percent) after eight months of treatment, whereas there were no substantial changes in the rate of colonization with Enterobacteriaceae among the placebo recipients throughout the study (P<0.005 for the comparison between groups at one and eight months) (Table 3).The mean vaginal pH fell from 5.5 ±0.7 at base line to 3.8 ±0.8 after one month and to 3.6 ±1.0 after eight months in the estriol-treated patients, whereas it changed little, from 5.8 ±1.2 to 6.2 ±1.2 and 6.1 ±2.0, in the placebo recipients (P<0.001 for the comparison between groups at one and eight months) (Table 3).
Despite the small numbers of patients enrolled, there appeared to be a relation between vaginal-colonization status and the risk of infection. Thus, urinary tract infections developed in 3 of the 23 estriol-treated women who were colonized with lactobacillus at one or eight months as compared with 7 of the 13 who were not colonized with lactobacillus. Of the 28 women with vaginal colonization with Enterobacteriaceae at either the one- or the eight-month visit, 7 of 10 in the estriol group and 14 of 18 in the placebo group had urinary tract infections.
Adverse Reactions
Localized adverse reactions consisted of vaginal irritation, burning, or itching and were observed in 10 of the estriol-treated women and 4 of the placebo recipients (Table 1). These reactions were mild and self-limited but caused the women to withdraw from the study. No systemic adverse reactions were observed.
Discussion
Urinary tract infections represent an important health problem for postmenopausal women1. Although the majority of such infections in these patients remain asymptomatic, some women have recurrent episodes of symptomatic infection. Our objectives in this study were to ascertain whether estrogen replacement would reduce the susceptibility of such women to recurrent urinary tract infection and, if so, whether the reduction was associated with alterations in vaginal colonization with lactobacilli. Using a randomized, double-blind, placebo-controlled design and an eight-month observation period, we found that topical estrogen treatment had a dramatic effect on the incidence of recurrent urinary tract infection. The considerable reduction in the frequency of symptomatic episodes of urinary tract infection in patients treated with estrogen also greatly reduced their use of antibiotics.
The use of topical estrogen was associated with a significant decrease in vaginal pH, an increase in the rate of vaginal colonization with lactobacilli, and a decrease in the rate of vaginal colonization with Enterobacteriaceae. These changes in colonizing microorganisms undoubtedly have a critical role in altering the susceptibility of postmenopausal women to urinary tract infections. In normal, fertile women, lactobacillus species are the predominant microorganisms in the vaginal flora and maintain the normally acidic vaginal pH through their metabolic activity (the generation of lactic acid from carbohydrates)6,7. Lactobacilli may protect the vagina against colonization by potential uropathogens through several mechanisms7-10. First, the maintenance of a low pH may itself be of direct importance. Stamey et al. observed that colonization of the vaginal introitus with E. coli is rarely noted at a vaginal pH below 4.5, but is significantly more common among women with recurrent urinary tract infections, many of whom have a vaginal pH above 4.59. Furthermore, E. coli strains from serogroups commonly associated with urinary tract infections survive better at a lower pH than serogroups not associated with urinary tract infections9. Second, some lactobacillus strains produce hydrogen peroxide, which may prevent vaginal colonization with uropathogens7,8. Finally, fragments of lactobacillus cell walls have been shown to prevent the attachment of E. coli to epithelial cells, perhaps by steric hindrance or by blocking potential sites of attachment10. Thus, through one or more of these mechanisms, the loss of lactobacillus colonization and the associated atrophy of the vaginal mucosa that normally occurs after menopause may increase the likelihood of recurrent urinary infections.
The use of a diaphragm with a spermicide by premenopausal women who had an increased susceptibility to recurrent urinary tract infections was associated with an increased vaginal pH, decreased colonization with lactobacilli, and increased introital colonization with Enterobacteriaceae11,12. These alterations in the vaginal flora may result from the fact that nonoxynol 9, at concentrations achieved in the vagina, is readily microbicidal to lactobacilli but not to E. coli or other uropathogens, which are highly resistant13. Thus, at least two factors that influence colonization with lactobacilli and other components of the normal vaginal flora -- the use of a diaphragm with a spermicide and the lack of estrogen -- appear to predispose women to recurrent urinary tract infections.
We studied topically applied estriol rather than the orally administered drug, since the former should be safer and should not produce systemic effects. Although estriol is absorbed after vaginal administration, according to its pharmacokinetic profile, the risk of persistently elevated serum levels with the topical dose used in this study is negligible. Mattsson and Cullberg,14 for example, showed that when a vaginal preparation of 0.5 mg of estriol was given to healthy postmenopausal women, no unconjugated estrogen could be measured in the serum after 24 hours. Furthermore, vaginal application of estriol leads to the normalization of the cervicovaginal mucosa, whereas the endometrium remains unaffected, suggesting the absence of any systemic estrogenic effect15. We observed no evidence of systemic toxicity in women using topical estrogen, and the side effects were limited to localized pruritus or burning. Although generally mild, these symptoms were irritating enough in 10 women to result in the cessation of treatment.
Our results support the hypothesis that estrogen deficiency is a major contributor to the pathogenesis of recurrent urinary tract infections in postmenopausal women and show that prolonged estrogen replacement with a topically applied vaginal cream safely and effectively prevents urinary tract infections in these patients. This preventive approach can be considered an alternative to the use of long-term low-dose antibiotics such as nitrofurantoin, co-trimoxazole, trimethoprim, cephalexin, or more recently, the fluoroquinolones. These regimens are effective16-20; however, topical estrogen may be particularly useful in patients in whom the prolonged use of antibiotics induces side effects, allergic reactions, drug interactions, or the emergence of multidrug-resistant microorganisms. The results of two previous open studies and one small controlled trial also suggest that orally administered estriol may prevent recurrent urinary infections in postmenopausal women6,21,22. However, in a case-control study of more than 23,000 older women attending general practice clinics in England, Orlander and associates found that estrogen use was associated with a twofold increase in the risk of a first episode of urinary tract infection23. Thus, the effects of oral estrogen use on initial and recurrent episodes of urinary tract infection in postmenopausal women require further evaluation.
Supported by a grant from Organon B.V. International, the Netherlands, and by a grant (DK-40045) from the National Institutes of Health.
Source Information
From the Infectious Disease Unit, Central Emek Hospital, and the Technion Faculty of Medicine, Haifa, Israel (R.R.), and the Department of Medicine, University of Washington, Seattle (W.E.S.).
Address reprint requests to Dr. Raz at the Infectious Disease Unit, Central Emek Hospital, Afula, 18101 Israel.
- References
References
1
Romano JM ,Kaye D . UTI in the elderly: common yet atypical. Geriatrics 1981;36:113-115
Web of Science | Medline2
Molander U ,Milsom I ,Ekelund P ,Mellstrom D ,Eriksson O . Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas 1990;12:113-120
CrossRef | Web of Science | Medline3
Lang WR . Vaginal acidity and pH: a review. Obstet Gynecol Surv 1955;10:546-560
CrossRef | Medline4
Stamey TA ,Sexton CC . The role of vaginal colonization with enterobacteriaceae in recurrent urinary infections. J Urol 1975;113:214-217
Web of Science | Medline5
Parsons CL ,Schmidt JD . Control of recurrent lower urinary tract infection in the postmenopausal woman. J Urol 1982;128:1224-1226
Web of Science | Medline6
Brandberg A ,Mellstrom D ,Samside G . Low dose oral estriol treatment in elderly women with urogenital infections. Acta Obstet Gynecol Scand Suppl 1987;140:33-38
CrossRef | Medline7
Eschenbach DA ,Davick PR ,Williams BL , et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989;27:251-256
Web of Science | Medline8
Klebanoff SJ ,Hillier SL ,Eschenbach DA ,Waltersdorph AM . Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J Infect Dis 1991;164:94-100
CrossRef | Web of Science | Medline9
Stamey TA ,Timothy M ,Millar M ,Mihara G . Recurrent urinary infections in adult women: the role of introital enterobacteria. Calif Med 1971;115:1-19
Medline10
Chan RC ,Reid G ,Irvin RT ,Bruce AW ,Costerton JW . Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun 1985;47:84-89
Web of Science | Medline11
Hooton TM ,Hillier S ,Johnson C ,Roberts PL ,Stamm WE . Escherichia coli bacteriuria and contraceptive method. JAMA 1991;265:64-69
CrossRef | Web of Science | Medline12
Hooton TM ,Fihn SD ,Johnson C ,Roberts PL ,Stamm WE . Association between bacterial vaginosis and acute cystitis in women using diaphragms. Arch Intern Med 1989;149:1932-1936
CrossRef | Web of Science | Medline13
Hooton TM ,Fennell CL ,Clark AM ,Stamm WE . Nonoxynol-9: differential antibacterial activity and enhancement of bacterial adherence to vaginal epithelial cells. J Infect Dis 1991;164:1216-1219
CrossRef | Web of Science | Medline14
Mattsson LA ,Cullberg G . Vaginal absorption of two estriol preparations: a comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983;62:393-396
CrossRef | Web of Science | Medline15
Trevoux R ,van der Velden WH ,Popovic D . Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduction 1982;6:101-10616
Raz R ,Boger S . Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. Antimicrob Agents Chemother 1991;35:1241-1242
Web of Science | Medline17
Stamm WE ,Counts GW ,Wagner KF , et al. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind placebo-controlled trial. Ann Intern Med 1980;92:770-775
Web of Science | Medline18
Stamm WE ,McKevitt M ,Roberts PL ,White NJ . Natural history of recurrent urinary tract infections in women. Rev Infect Dis 1991;13:77-84
CrossRef | Medline19
Nicolle LE ,Harding GK ,Thomson M ,Kennedy J ,Urias B ,Ronald AR . Efficacy of five years of continuous, low-dose trimethoprim-sulfamethoxazole prophylaxis for urinary tract infection. J Infect Dis 1988;157:1239-1242
CrossRef | Web of Science | Medline20
Harding GKM ,Ronald AR . A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. N Engl J Med 1974;291:597-601
Full Text | Web of Science | Medline21
Kirkengen AL ,Andersen P ,Gjersoe E ,Johannessen GR ,Johnsen N ,Bodd E . Oestriol in the prophylactic treatment of recurrent urinary tract infections in postmenopausal women. Scand J Prim Health Care 1992;10:139-142
CrossRef | Medline22
Privette M ,Cade R ,Peterson J ,Mars D . Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50:24-27
CrossRef | Medline23
Orlander JD ,Jick SS ,Dean AD ,Jick H . Urinary tract infections and estrogen use in older women. J Am Geriatr Soc 1992;40:817-820
Web of Science | Medline
- Citing Articles (198)
Citing Articles
1
Henrik Griesser, Stefan Skonietzki, Thomas Fischer, Karin Fielder, Marija Suesskind. (2012) Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas
CrossRef2
Sandy B. Nosseir, Lawrence R. Lind, Harvey A. Winkler. (2011) Recurrent Uncomplicated Urinary Tract Infections in Women. Journal of Women's Health111202101913003
CrossRef3
C.D.J. Heijer, E.E. Stobberingh. (2011) Recidiverende urineweginfecties bij oudere mannen en vrouwen. Bijblijven
CrossRef4
Cara L. Grimes, Emily S. Lukacz. (2011) Urinary Tract Infections. Female Pelvic Medicine & Reconstructive Surgery 17:6, 272-278
CrossRef5
S. James Matthews, Jason W. Lancaster. (2011) Urinary Tract Infections in the Elderly Population. The American Journal of Geriatric Pharmacotherapy 9:5, 286-309
CrossRef6
F.M.E. Wagenlehner, W. Vahlensieck, H.-W. Bauer, W. Weidner, K.G. Naber, H.-J. Piechota. (2011) Primär- und Sekundärprävention von Harnwegsinfektionen. Der Urologe 50:10, 1248-1256
CrossRef7
Michelle E. Koski, Christopher J. Chermansky. (2011) Does Estrogen Have Any Real Effect on Voiding Dysfunction in Women?. Current Urology Reports 12:5, 345-350
CrossRef8
Mary Panjari, Susan R. Davis. (2011) Vaginal DHEA to treat menopause related atrophy: A review of the evidence. Maturitas 70:1, 22-25
CrossRef9
M. J. Enzler, E. Berbari, D. R. Osmon. (2011) Antimicrobial Prophylaxis in Adults. Mayo Clinic Proceedings 86:7, 686-701
CrossRef10
Giampiero Capobianco, Ermes Donolo, Gianna Borghero, Francesco Dessole, Pier Luigi Cherchi, Salvatore Dessole. (2011) Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Archives of Gynecology and Obstetrics
CrossRef11
Dudley Robinson, Linda Cardozo. (2011) Estrogens and the lower urinary tract. Neurourology and Urodynamics 30:5, 754-757
CrossRef12
Mansor Fazliana, Nubia L. Ramos, Petra Lüthje, Musa Sekikubo, Åsa Holm, W.M. Wan Nazaimoon, Annelie Brauner. (2011) Labisia pumila var. alata reduces bacterial load by inducing uroepithelial cell apoptosis. Journal of Ethnopharmacology 136:1, 111-116
CrossRef13
Ahmed S. El-Hefnawy, Adel Nabeeh, Essam El Sawy, Bassem S. Wadie. (2011) Urinary tract infection before and after mid-urethral slings: culture-proven diagnosis and analysis of risk factors. International Urology and Nephrology 43:2, 345-351
CrossRef14
Katherine E. Twombley, Mouin G. Seikaly. (2011) New paradigms for the use of prebiotics, probiotics, and synbiotics in renal disease. Dialysis & Transplantation 40:5, 200-204
CrossRef15
Gwendolen T. Buhr, Liza Genao, Heidi K. White. (2011) Urinary Tract Infections in Long-Term Care Residents. Clinics in Geriatric Medicine 27:2, 229-239
CrossRef16
Elodi J. Dielubanza, Anthony J. Schaeffer. (2011) Urinary Tract Infections in Women. Medical Clinics of North America 95:1, 27-41
CrossRef17
Antonia Andreu, Juana Cacho, Amparo Coira, José Antonio Lepe. (2011) Diagnóstico microbiológico de las infecciones del tracto urinario. Enfermedades Infecciosas y Microbiología Clínica 29:1, 52-57
CrossRef18
Raul Raz. (2011) Urinary Tract Infection in Postmenopausal Women. Korean Journal of Urology 52:12, 801
CrossRef19
Jun Mo Kim, Tae Hee Kim. (2011) Changes of Urinary Tract after Menopause and Effectiveness of Menopausal Hormone Replacement Therapy. The Journal of Korean Society of Menopause 17:3, 136
CrossRef20
F. Bruyère, J.-P. Boiteux. (2011) Epidemiología, diagnóstico y tratamiento de las cistitis agudas aisladas o recidivantes del adulto. EMC - Urología 43:4, 1-12
CrossRef21
Karen J. Leckie. (2010) What is the evidence for the role of oestrogen in the prevention of recurrent urinary tract infections in postmenopausal women? An evidence-based review. Journal of Clinical Gerontology and Geriatrics 1:2, 31-35
CrossRef22
J. Curtis Nickel, Daniel A. Shoskes, Karen Irvine-Bird. (2010) Prevalence and Impact of Bacteriuria and/or Urinary Tract Infection in Interstitial Cystitis/Painful Bladder Syndrome. Urology 76:4, 799-803
CrossRef23
Miranda A Farage, Kenneth W Miller, William Ledger. (2010) Confronting the challenges of postmenopausal urogenital health. Aging Health 6:5, 611-626
CrossRef24
Shingo Yamamoto, Yoshihide Higuchi, Michio Nojima. (2010) Current therapy of acute uncomplicated cystitis. International Journal of Urology 17:5, 450-456
CrossRef25
Hosam Ghazy Elbanna, Amr Medhat Abbas, Khaled Zalata, Mohamed Farid, Wageh Ghanum, Mohamed Youssef, Waleed Mohamed Thabet, Saleh Awady, Mohamed H. Abd El-Sattar. (2010) Effects of ovarian failure on submucosal collagen and blood vessels of the anal canal in postmenopausal women. International Journal of Colorectal Disease 25:4, 477-483
CrossRef26
Dong-Gi Lee, Jeong-Je Cho, Hun Kuk Park, Dae Kyung Kim, Jin Il Kim, Sung-Goo Chang, Sun-Ju Lee. (2010) Preventive Effects of Hyaluronic Acid on Escherichia coli-induced Urinary Tract Infection in Rat. Urology 75:4, 949-954
CrossRef27
David F. Archer. (2010) Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 17:1, 194-203
CrossRef28
Francisco Cruz, Miriam Dambros, Kurt G. Naber, Hartwig W. Bauer, Gabriel Cozma. (2009) Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative. European Urology Supplements 8:9, 762-768
CrossRef29
L.E. Nicolle. (2009) Urinary Tract Infections in the Elderly. Clinics in Geriatric Medicine 25:3, 423-436
CrossRef30
Bernard T. Haylen, Joseph Lee, Sue Husselbee, Matthew Law, Jialun Zhou. (2009) Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction. International Urogynecology Journal 20:7, 837-842
CrossRef31
David G. Weismiller. (2009) Menopause. Primary Care: Clinics in Office Practice 36:1, 199-226
CrossRef32
Maurizio Serati, Stefano Salvatore, Stefano Uccella, Linda Cardozo, Pierfrancesco Bolis. (2009) Is There a Synergistic Effect of Topical Oestrogens When Administered with Antimuscarinics in the Treatment of Symptomatic Detrusor Overactivity?. European Urology 55:3, 713-720
CrossRef33
Tetsuya Miura, Kazushi Tanaka, Yuzo Nakano, Soichi Arakawa, Atsushi Takenaka, Masato Fujisawa. (2009) The Impact of Decreasing Urinary IgA Levels on Decreased Bacteriuria in a Rat Model of Ileal Augmented Bladder. The Journal of Urology 181:1, 372-378
CrossRef34
James A. Simon. (2009) Vulvovaginal atrophy. Menopause 16:1, 5-7
CrossRef35
Rogerio A. Lobo. 2009. Menopause and Aging. , 325-355.
CrossRef36
D. Harari, C. Igbedioh. (2008) Restoring continence in frail older people living in the community: what factors influence successful treatment outcomes?. Age and Ageing 38:2, 228-233
CrossRef37
Matthew E. Falagas, Stavros Athanasiou, Christos Iavazzo, Theodoros Tokas, Aris Antsaklis. (2008) Urinary tract infections after pelvic floor gynecological surgery: prevalence and effect of antimicrobial prophylaxis. A systematic review. International Urogynecology Journal 19:8, 1165-1172
CrossRef38
Filiz Çayan, Mesut Tek, Ebru Ballı, Sinem Öztuna, Sinan Karazindiyanoğlu, Selahittin Çayan. (2008) The effect of testosterone alone and testosterone+estradiol therapy on bladder functions and smooth muscle/collagen content in surgically menopause induced rats. Maturitas 60:3-4, 248-252
CrossRef39
Raymond T. Foster. (2008) Uncomplicated Urinary Tract Infections in Women. Obstetrics and Gynecology Clinics of North America 35:2, 235-248
CrossRef40
Adam Dahn, Sheri Saunders, Jo-Anne Hammond, David Carter, Pirkka Kirjavainen, Kingsley Anukam, Gregor Reid. (2008) Effect of bacterial vaginosis, Lactobacillus and Premarin estrogen replacement therapy on vaginal gene expression changes. Microbes and Infection 10:6, 620-627
CrossRef41
Lee P. Shulman, David J. Portman, Won Chan Lee, Sanjeev Balu, Ashish V. Joshi, David Cobden, Qin Wang, Chris L. Pashos. (2008) A Retrospective Managed Care Claims Data Analysis of Medication Adherence to Vaginal Estrogen Therapy: Implications for Clinical Practice. Journal of Women's Health 17:4, 569-578
CrossRef42
Lindsay E Nicolle. (2008) Urinary tract infections in older people. Reviews in Clinical Gerontology 18:02, 103
CrossRef43
Ruth M de Souza, Jonathon Olsburgh. (2008) Urinary tract infection in the renal transplant patient. Nature Clinical Practice Nephrology 4:5, 252-264
CrossRef44
Carla Perrotta, Mireya Aznar, Raul Mejia, Xavier Albert, Cheen Werne Ng, Carla Perrotta. 2008. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. .
CrossRef45
Lindsay E. Nicolle. (2008) Uncomplicated Urinary Tract Infection in Adults Including Uncomplicated Pyelonephritis. Urologic Clinics of North America 35:1, 1-12
CrossRef46
Dudley Robinson, Linda Cardozo. 2008. HORMONAL INFLUENCES ON THE FEMALE GENITAL AND LOWER URINARY TRACTS. , 59-68.
CrossRef47
Christine A. Heisler, John B. Gebhart. (2008) Urinary Tract Infection in the Adult Female. Journal of Pelvic Medicine and Surgery 14:1, 1-14
CrossRef48
Nina E. Tolkoff-Rubin, Robert H. Rubin. 2008. Therapy of Urinary Tract Infection. , 447-454.
CrossRef49
Amanda M. Macejko, Anthony J. Schaeffer. 2008. URINARY TRACT INFECTIONS IN WOMEN. , 847-856.
CrossRef50
Ilana Beth Addis. 2008. SOCIAL IMPACT OF URINARY INCONTINENCE AND PELVIC FLOOR DYSFUNCTION. , 69-74.
CrossRef51
Paul Nyirjesy. (2007) Postmenopausal vaginitis. Current Infectious Disease Reports 9:6, 480-484
CrossRef52
Manisha Juthani-Mehta. (2007) Asymptomatic Bacteriuria and Urinary Tract Infection in Older Adults. Clinics in Geriatric Medicine 23:3, 585-594
CrossRef53
Kae-Yng OU, Yu-Chieh CHEN, Shih-Cheng HSU, Eing-Mei TSAI. (2007) Topical vaginal oestrogen cream used for treatment of burn injury of vaginal mucosa after misapplication of 100% acetic acid in a perimenopausal woman: A case report. Australian and New Zealand Journal of Obstetrics and Gynaecology 47:4, 345-346
CrossRef54
Michael Cirigliano. (2007) Bioidentical Hormone Therapy: A Review of the Evidence. Journal of Women's Health 16:5, 600-631
CrossRef55
&NA;. (2007) The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. Menopause 14:3, 357-369
CrossRef56
Sheri Saunders, Alan Bocking, John Challis, Gregor Reid. (2007) Effect of Lactobacillus challenge on Gardnerella vaginalis biofilms. Colloids and Surfaces B: Biointerfaces 55:2, 138-142
CrossRef57
GURIT E. BIRNBAUM, OHAD COHEN, VERED WERTHEIMER. (2007) Is it all about intimacy? Age, menopausal status, and women?s sexuality. Personal Relationships 14:1, 167-185
CrossRef58
John A. Taylor, George A. Kuchel. (2006) Detrusor Underactivity: Clinical Features and Pathogenesis of an Underdiagnosed Geriatric Condition. Journal of the American Geriatrics Society 54:12, 1920-1932
CrossRef59
Randolph E. Regal, Co Q. D. Pham, Thomas R. Bostwick. (2006) Urinary Tract Infections in Extended Care Facilities: Preventive Management Strategies. The Consultant Pharmacist 21:5, 400-409
CrossRef60
Shelley R. Salpeter, Judith M. E. Walsh, Elizabeth Greyber, Edwin E. Salpeter. (2006) BRIEF REPORT: Coronary Heart Disease Events Associated with Hormone Therapy in Younger and Older Women. A Meta-Analysis. Journal of General Internal Medicine 21:4, 363-366
CrossRef61
Selahittin Çayan, Bülent Canpolat, Filiz Çayan, Necat Yιlmaz, Akif Kartal, İzzet O??uz, Erdem Akbay. (2006) The effect of chronic inflammatory condition of the bladder and estrogen replacement therapy on bladder functions and histology in surgically menopause and chronic cystitis induced rats. Neurourology and Urodynamics 25:2, 194-201
CrossRef62
Gregor Reid. (2006) Prevention and treatment of urogenital infections and complications: lactobacilli's multi-pronged effects1. Microbial Ecology in Health and Disease 18:3-4, 181-186
CrossRef63
Antonia Andreu. (2005) Patogenia de las infecciones del tracto urinario. Enfermedades Infecciosas y Microbiología Clínica 23, 15-21
CrossRef64
Carlos Pigrau-Serrallach. (2005) Infecciones urinarias recurrentes. Enfermedades Infecciosas y Microbiología Clínica 23, 28-39
CrossRef65
B. Banas, B. K. Krämer. (2005) Therapie und Prophylaxe rezidivierender Harnwegsinfekte. Der Internist 46:12, 1360-1366
CrossRef66
A FRANCO. (2005) Recurrent urinary tract infections. Best Practice & Research Clinical Obstetrics & Gynaecology 19:6, 861-873
CrossRef67
George I Gorodeski. (2005) Effects of estrogen on proton secretion via the apical membrane in vaginal-ectocervical epithelial cells of postmenopausal women. Menopause 12:6, 679-684
CrossRef68
David M. Stieb, Marc Smith Doiron, Philip Blagden, Richard T. Burnett. (2005) Estimating the Public Health Burden Attributable to Air Pollution: An Illustration Using the Development of an Alternative Air Quality Index. Journal of Toxicology and Environmental Health, Part A 68:13-14, 1275-1288
CrossRef69
Lindsay E Nicolle. (2005) Managing recurrent urinary tract infections in women. Women's Health 1:1, 39-50
CrossRef70
Elizabeth Barrett-Connor, Deborah Grady, Marcia L. Stefanick. (2005) THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY. Annual Review of Public Health 26:1, 115-140
CrossRef71
Oguzhan Yildiz, Yasar Ozgok, Melik Seyrek, Ismail Un, Mete Kilciler, Meral Tuncer. (2005) Influence of estradiol pretreatment on antimuscarinic action of oxybutynin in rat detrusor muscle. Urology 65:4, 800-803
CrossRef72
Germar-M. Pinggera, Gudrun Feuchtner, Ferdinand Frauscher, Peter Rehder, Hannes Strasser, Georg Bartsch, Ralf Herwig. (2005) Effects of Local Estrogen Therapy on Recurrent Urinary Tract Infections in Young Females under Oral Contraceptives. European Urology 47:2, 243-249
CrossRef73
Santiago Palacios, Camil Castelo-Branco, Marı́a Jesús Cancelo, Francisco Vázquez. (2005) Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 50:2, 98-104
CrossRef74
Florian M E Wagenlehner, Kurt G Naber, Wolfgang Weidner. (2005) Asymptomatic Bacteriuria in Elderly Patients. Drugs & Aging 22:10, 801-807
CrossRef75
Gordana Bojic-Milicevic, Momir Mikov, Radomir Dautovic. (2005) Common errors in diagnosis and management of urinary tract infections: Microbiological aspects. Medicinski pregled 58:7-8, 380-387
CrossRef76
Newton G. Osborne. (2004) Urinary-Tract Infections: Acute and Preventive Therapy for the Female Patient. Journal of Gynecologic Surgery 20:4, 135-138
CrossRef77
Dudley Robinson, Linda Cardozo. (2004) Oestrogens and the lower urinary tract. BJOG: An International Journal of Obstetrics & Gynaecology 111, 10-14
CrossRef78
&NA;. (2004) Genitourinary Tract Changes. Obstetrics & Gynecology 104:Supplement, 56S-61S
CrossRef79
Gregor Reid, Estelle Devillard. (2004) Probiotics for Mother and Child. Journal of Clinical Gastroenterology 38:Supplement 2, S94-S101
CrossRef80
Nancy J Alexander, Edward Baker, Marc Kaptein, Ulrich Karck, Leslie Miller, Edio Zampaglione. (2004) Why consider vaginal drug administration?. Fertility and Sterility 82:1, 1-12
CrossRef81
Shelley R. Salpeter, Judith M.E. Walsh, Elizabeth Greyber, Thomas M. Ormiston, Edwin E. Salpeter. (2004) Mortality Associated with Hormone Replacement Therapy in Younger and Older Women. A Meta-analysis. Journal of General Internal Medicine 19:7, 791-804
CrossRef82
C. Constantinides, T. Manousakas, P. Nikolopoulos, A. Stanitsas, K. Haritopoulos, A. Giannopoulos. (2004) Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU International 93:9, 1262-1266
CrossRef83
Gregor Reid, Jeremy Burton, Jo-Anne Hammond, Andrew W. Bruce. (2004) Nucleic Acid-Based Diagnosis of Bacterial Vaginosis and Improved Management Using Probiotic Lactobacilli. Journal of Medicinal Food 7:2, 223-228
CrossRef84
S Roy, J.C Caillouette, T Roy, J.S Faden. (2004) Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. American Journal of Obstetrics and Gynecology 190:5, 1272-1277
CrossRef85
Lisa A. Boothby, Paul L. Doering, Simon Kipersztok. (2004) Bioidentical hormone therapy: a review. Menopause 11:3, 356-367
CrossRef86
Sean P McLaughlin, Culley C Carson. (2004) Urinary tract infections in women. Medical Clinics of North America 88:2, 417-429
CrossRef87
JEFFREY A. STERN, YI-CHING HSIEH, ANTHONY J. SCHAEFFER. (2004) Residual Urine in an Elderly Female Population: Novel Implications for Oral Estrogen Replacement and Impact on Recurrent Urinary Tract Infection. The Journal of Urology 171:2, 768-770
CrossRef88
Chesley L. Richards. (2004) Urinary tract infections in the frail elderly: Issues for diagnosis, treatment and prevention. International Urology and Nephrology 36:3, 457-463
CrossRef89
Salvatore Dessole, Giovanni Rubattu, Guido Ambrosini, Omar Gallo, Giampiero Capobianco, Pier Luigi Cherchi, Roberto Marci, Erich Cosmi. (2004) Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 11:1, 49-56
CrossRef90
Jack D. Sobel. (2003) Estrogen replacement therapy to prevent recurrent urinary tract infection in postmenopausal women. Current Infectious Disease Reports 5:6, 479-480
CrossRef91
Dudley Robinson, Linda D Cardozo. (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62:4, 45-51
CrossRef92
E. Ann Gormley. (2003) Recurrent urinary tract infection in women: Emerging concepts regarding etiology and treatment considerations. Current Urology Reports 4:5, 399-403
CrossRef93
Fihn, Stephan D., . (2003) Acute Uncomplicated Urinary Tract Infection in Women. New England Journal of Medicine 349:3, 259-266
Full Text94
Susan R. Davis, Sara Knight, Vikki White, Caroline Claridge, Barbara J. Davis, Robin Bell. (2003) Climacteric symptoms among indigenous Australian women and a model for the use of culturally relevant art in health promotion. Menopause 10:4, 345-351
CrossRef95
Laura Francisco. (2003) Is Bio-Identical Hormone Therapy Fact or Fairy Tale?. The Nurse Practitioner 28:7, 39-44
CrossRef96
Björn Wullt. (2003) Erratum to “The role of P fimbriae for Escherichia coli establishment and mucosal inflammation in the human urinary tract”. International Journal of Antimicrobial Agents 21:6, 605-621
CrossRef97
Ann Stapleton. (2003) Novel approaches to prevention of urinary tract infections. Infectious Disease Clinics of North America 17:2, 457-471
CrossRef98
R. Raz, R. Colodner, Y. Rohana, S. Battino, E. Rottensterich, I. Wasser, W. Stamm. (2003) Effectiveness of Estriol-Containing Vaginal Pessaries and Nitrofurantoin Macrocrystal Therapy in the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women. Clinical Infectious Diseases 36:11, 1362-1368
CrossRef99
C. Bertero. (2003) What do women think about menopause? A qualitative study of women's expectations, apprehensions and knowledge about the climacteric period. International Nursing Review 50:2, 109-118
CrossRef100
Dudley Robinson, Linda Cardozo. (2003) Urogenital effects of hormone therapy. Best Practice & Research Clinical Endocrinology & Metabolism 17:1, 91-104
CrossRef101
Gregor Reid, Duane Charbonneau, Julie Erb, Barbara Kochanowski, Dee Beuerman, Russ Poehner, Andrew W. Bruce. (2003) Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology & Medical Microbiology 35:2, 131-134
CrossRef102
Carolyn Crandall. (2002) Vaginal Estrogen Preparations: A Review of Safety and Efficacy for Vaginal Atrophy. Journal of Women's Health 11:10, 857-877
CrossRef103
Joseph G Ouslander. (2002) Geriatric considerations in the diagnosis and management of overactive bladder. Urology 60:5, 50-55
CrossRef104
Peter L. Dwyer, Mary OʼReilly. (2002) Recurrent urinary tract infection in the female. Current Opinion in Obstetrics and Gynecology 14:5, 537-543
CrossRef105
Jane L. Miller, John N. Krieger. (2002) Urinary tract infections. Urologic Clinics of North America 29:3, 695-699
CrossRef106
Calvin M. Kunin, Cynthia Evans, Deborah Bartholomew, D. Gregory Bates. (2002) The Antimicrobial Defense Mechanism of the Female Urethra: A Reassessment. The Journal of Urology 168:2, 413-419
CrossRef107
CALVIN M. KUNIN, CYNTHIA EVANS, DEBORAH BARTHOLOMEW, D. GREGORY BATES. (2002) The Antimicrobial Defense Mechanism of the Female Urethra:. The Journal of Urology413-419
CrossRef108
Cynthia Maloney. (2002) Estrogen & Recurrent UTI in Postmenopausal Women. AJN, American Journal of Nursing 102:8, 44-53
CrossRef109
Björn Wullt, Göran Bergsten, Martin Samuelsson, Catharina Svanborg. (2002) The role of P fimbriae for Escherichia coli establishment and mucosal inflammation in the human urinary tract. International Journal of Antimicrobial Agents 19:6, 522-538
CrossRef110
S. Ishitoya, S. Yamamoto, K. Mitsumori, O. Ogawa, A. Terai. (2002) Non-secretor status is associated with female acute uncomplicated pyelonephritis. BJU International 89:9, 851-854
CrossRef111
Gregor Reid, Jeremy Burton. (2002) Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes and Infection 4:3, 319-324
CrossRef112
Gregor Reid. (2002) Probiotics for Urogenital Health. Nutrition in Clinical Care 5:1, 3-8
CrossRef113
Ruby Meiland, Suzanne E. Geerlings, Andy I.M. Hoepelman. (2002) Management of Bacterial Urinary Tract Infections in Adult Patients with Diabetes Mellitus. Drugs 62:13, 1859-1868
CrossRef114
Tetsuro Matsumoto. (2001) Urinary tract infections in the elderly. Current Urology Reports 2:4, 330-333
CrossRef115
Amanda A. Deeks, Marita P. McCabe. (2001) Sexual function and the menopausal woman: The importance of age and partner's sexual functioning. Journal of Sex Research 38:3, 219-225
CrossRef116
Peter J. Blakeman, Paul Hilton, Judith N. Bulmer. (2001) Cellular proliferation in the female lower urinary tract with reference to oestrogen status. BJOG: An International Journal of Obstetrics and Gynaecology 108:8, 813-816
CrossRef117
Betsy Foxman, Patricia Somsel, Patricia Tallman, Brenda Gillespie, Raul Raz, Raul Colodner, Deepika Kandula, Jack D. Sobel. (2001) Urinary tract infection among women aged 40 to 65. Journal of Clinical Epidemiology 54:7, 710-718
CrossRef118
A.Y. Rostom. (2001) The Management of Menopausal Sequelae in Patients with Breast Cancer. Clinical Oncology 13:3, 174-180
CrossRef119
Joseph G. Ouslander, Gail A. Greendale, Gwen Uman, Carol Lee, Wendy Paul, John Schnelle. (2001) Effects of Oral Estrogen and Progestin on the Lower Urinary Tract Among Female Nursing Home Residents. Journal of the American Geriatrics Society 49:6, 803-807
CrossRef120
A.J. Schaeffer, Nithya Rajan, Qing Cao, B.E. Anderson, Denise L. Pruden, Julia Sensibar, J.L. Duncan. (2001) Host pathogenesis in urinary tract infections. International Journal of Antimicrobial Agents 17:4, 245-251
CrossRef121
Thomas M Hooton. (2001) Recurrent urinary tract infection in women. International Journal of Antimicrobial Agents 17:4, 259-268
CrossRef122
Laurie A. Willhite, Mary Beth O'Connell. (2001) Urogenital Atrophy: Prevention and Treatment. Pharmacotherapy: Official Journal of the American College of Clinical Pharmacy 21:4, 464-480
CrossRef123
R Raz. (2001) Postmenopausal women with recurrent UTI. International Journal of Antimicrobial Agents 17:4, 269-271
CrossRef124
Gregor Reid, Andrew W. Bruce. (2001) Selection of Lactobacillus Strains for Urogenital Probiotic Applications. The Journal of Infectious Diseases 183:s1, S77-S80
CrossRef125
C MALONEY, M OLIVER. (2001) Effect of Local Conjugated Estrogens on Vaginal pH in Elderly Women. Journal of the American Medical Directors Association 2:2, 51-55
CrossRef126
Walter E. Stamm, S. Ragnar Norrby. (2001) Urinary Tract Infections: Disease Panorama and Challenges. The Journal of Infectious Diseases 183:s1, S1-S4
CrossRef127
Raul Raz. (2001) Hormone Replacement Therapy or Prophylaxis in Postmenopausal Women with Recurrent Urinary Tract Infection. The Journal of Infectious Diseases 183:s1, S74-S76
CrossRef128
Lindsay E. Nicolle, the SHEA Long‐Term–Care Committee*. (2001) Urinary Tract Infections in Long‐Term–Care Facilities • . Infection Control and Hospital Epidemiology 22:3, 167-175
CrossRef129
B. Larsen, G. R. G. Monif. (2001) Understanding the Bacterial Flora of the Female Genital Tract. Clinical Infectious Diseases 32:4, e69-e77
CrossRef130
Hideo Itoi, Hisanori Minakami, Ryuhiko Iwasaki, Ikuo Sato. (2000) Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas 36:3, 217-222
CrossRef131
L. E. Nicolle, T. T. Yoshikawa. (2000) Urinary Tract Infection in Long-Term-Care Facility Residents. Clinical Infectious Diseases 31:3, 757-761
CrossRef132
David A. Eschenbach, Dorothy L. Patton, Amalia Meier, Soe Soe Thwin, Jan Aura, Ann Stapleton, Thomas M. Hooton. (2000) Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception 62:3, 107-112
CrossRef133
Andrew Hextall. (2000) Oestrogens and lower urinary tract function. Maturitas 36:2, 83-92
CrossRef134
P Blakeman. (2000) Cellular proliferation in the female lower urinary tract with reference to oestrogen status. British Journal of Obstetrics and Gynaecology 108:8, 813-816
CrossRef135
Irvin H Hirsch. (2000) Integrative urology: a spectrum of complementary and alternative therapy. Urology 56:2, 185-189
CrossRef136
P.J. Blakeman, P. Hilton, J.N. Bulmer. (2000) Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU International 86:1, 32-38
CrossRef137
P Tellier, P Godeau. (2000) Ménopause et hormonothérapie substitutive. La Revue de Médecine Interne 21:5, 445-457
CrossRef138
Holly Mattix, Ajay K. Singh. (2000) Estrogen replacement therapy: implications for postmenopausal women with end-stage renal disease. Current Opinion in Nephrology and Hypertension 9:3, 207-214
CrossRef139
Michael O Sator, Fritz Nagele, Paul Sator, Sanja Travica, Doris Gruber, Johannes C Huber. (2000) Clinical profile of a new hormone replacement therapy containing 2 mg 17β-estradiol and 10 mg dydrogesterone. Maturitas 34:3, 267-273
CrossRef140
Ulla Molander, Leif Arvidsson, Ian Milsom, Torsten Sandberg. (2000) A longitudinal cohort study of elderly women with urinary tract infections. Maturitas 34:2, 127-131
CrossRef141
Stephan Madersbacher, Florian Thalhammer, Michael Marberger. (2000) Pathogenesis and management of recurrent urinary tract infection in women. Current Opinion in Urology 10:1, 29-33
CrossRef142
R. Raz, Y. Gennesin, J. Wasser, Z. Stoler, S. Rosenfeld, E. Rottensterich, W. E. Stamm. (2000) Recurrent Urinary Tract Infections in Postmenopausal Women. Clinical Infectious Diseases 30:1, 152-156
CrossRef143
Gregor Reid, Lindsay E. Nicolle. (1999) ASYMPTOMATIC BACTERIURIA IN SPINAL CORD PATIENTS AND THE ELDERLY. Urologic Clinics of North America 26:4, 789-795
CrossRef144
Durwood E. Neal. (1999) HOST DEFENSE MECHANISMS IN URINARY TRACT INFECTIONS. Urologic Clinics of North America 26:4, 677-686
CrossRef145
Betsy Foxman. (1999) Urinary tract infection in postmenopausal women. Current Infectious Disease Reports 1:4, 367-370
CrossRef146
Jack D. Sobel. (1999) Is there a protective role for vaginal flora?. Current Infectious Disease Reports 1:4, 379-383
CrossRef147
JAMES A. ROBERTS, M. BERNICE KAACK, RICHARD M. HARRISON, ROGER KLOPP, WILLIAM ERSHLER. (1999) BLADDER INFECTION IN THE MENOPAUSAL MONKEY. The Journal of Urology 162:1, 254-257
CrossRef148
Walter J. Hopkins, David T. Uehling, David S. Wargowski. (1999) Evaluation of a familial predisposition to recurrent urinary tract infections in women. American Journal of Medical Genetics 83:5, 422-424
CrossRef149
Elina Hemminki, Sinikka Sihvo. (1999) Finnish physicians’ opinions of vaginal estriol in self-care. Maturitas 31:3, 241-247
CrossRef150
Gail A Greendale, Nancy P Lee, Edga R Arriola. (1999) The menopause. The Lancet 353:9152, 571-580
CrossRef151
Kurt G. Naber. (1999) Short-term therapy of acute uncomplicated cystitis. Current Opinion in Urology 9:1, 57-64
CrossRef152
A.L.M Kok, C.W Burger, P.H.M van de Weijer, G.A Voetberg, E.R.A Peters-Muller, P Kenemans. (1999) Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study. Maturitas 31:2, 143-149
CrossRef153
Ann Stapleton. (1999) Prevention of recurrent urinary-tract infections in women. The Lancet 353:9146, 7-8
CrossRef154
Walter J. Hopkins, Dennis M. Heisey, David T. Uehling. (1999) Association of human leucocyte antigen phenotype with vaccine efficacy in patients receiving vaginal mucosal immunization for recurrent urinary tract infection. Vaccine 17:2, 169-171
CrossRef155
NEWTON G. OSBORNE. (1999) Urinary Tract Infections in Gynecology: Special Issues of Diagnosis and Management. Journal of Gynecologic Surgery 15:4, 207-208
CrossRef156
A.J. Schaeffer. (1998) Aetiopathology and pathogenesis of urogenital infections. Andrologia 30:S1, 3-6
CrossRef157
Jason D. Engel, Anthony J. Schaeffer. (1998) EVALUATION OF AND ANTIMICROBIAL THERAPY FOR RECURRENT URINARY TRACT INFECTIONS IN WOMEN. Urologic Clinics of North America 25:4, 685-701
CrossRef158
A Author. (1998) Urinary tract infection in elderly women. International Journal of Antimicrobial Agents 10:3, 177-179
CrossRef159
Sumana Chompootaweep, Pongpun Nunthapisud, Prasert Trivijitsilp, Prasertsri Sentrakul, Nikorn Dusitsin. (1998) The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: A comparative study*. Clinical Pharmacology & Therapeutics 64:2, 204-210
CrossRef160
X Albert, V Gosalbes, I Huertas, I Pereiró, J Sanfélix. 1998. Interventions for preventing recurrent urinary tract infection in women. .
CrossRef161
BJORN WULLT, HUGH CONNELL, PIOTR ROLLANO, WIKING MANSSON, STIG COLLEEN, CATHARINA SVANBORG. (1998) URODYNAMIC FACTORS INFLUENCE THE DURATION OF ESCHERICHIA COLI BACTERIURIA IN DELIBERATELY COLONIZED CASES. The Journal of Urology 159:6, 2057-2062
CrossRef162
BJORN WULLT, HUGH CONNELL, PIOTR ROLLANO, WIKING MANSSON, STIG COLLEEN, CATHARINA SVANBORG. (1998) URODYNAMIC FACTORS INFLUENCE THE DURATION OF ESCHERICHIA COLI BACTERIURIA IN DELIBERATELY COLONIZED CASES. The Journal of Urology2057-2062
CrossRef163
Böran Samsioe. (1998) Urogenital aging—A hidden problem. American Journal of Obstetrics and Gynecology 178:5, S245-S249
CrossRef164
Linda Cardozo, Christopher Benness, Denise Abbott. (1998) Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. BJOG: An International Journal of Obstetrics and Gynaecology 105:4, 403-407
CrossRef165
G Oettling, H.B.G Franz. (1998) Mapping of androgen, estrogen and progesterone receptors in the anal continence organ. European Journal of Obstetrics & Gynecology and Reproductive Biology 77:2, 211-216
CrossRef166
J. C. Stevenson, U. Gaspard, B. Avouac, C. Bricaire, L. Grees Cardozo, P. Collins, J. P. Devogelaer, M. Dören, C. Gennari, J. M. Kaufman, F. Kuttenn, J. D. Ringe, C. Scarafiotti, L. Vanhaelst, L. Zichella, R. Ziegler, J. Y. Reginster. (1998) Points to consider for the development of new indications for hormone replacement therapies and estrogen-like molecules. Climacteric 1:1, 12-17
CrossRef167
BEN J. BARNETT, DAVID S. STEPHENS. (1997) Urinary Tract Infection: An Overview. The American Journal of the Medical Sciences 314:4, 245-249
CrossRef168
LOTIKA PANDIT, JOSEPH G. OUSLANDER. (1997) Postmenopausal Vaginal Atrophy and Atrophic Vaginitis. The American Journal of the Medical Sciences 314:4, 228-231
CrossRef169
Nina E. Tolkoff-Rubin, Robert H. Rubin. (1997) URINARY TRACT INFECTION IN THE IMMUNOCOMPROMISED HOST. Infectious Disease Clinics of North America 11:3, 707-717
CrossRef170
Hideo Itoi, Hisanori Minakami, Ikuo Sato. (1997) Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-α-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas 28:1, 11-17
CrossRef171
Lindsay E. Nicolle. (1997) ASYMPTOMATIC BACTERIURIA IN THE ELDERLY. Infectious Disease Clinics of North America 11:3, 647-662
CrossRef172
Ann Stapleton, Walter E. Stamm. (1997) PREVENTION OF URINARY TRACT INFECTION. Infectious Disease Clinics of North America 11:3, 719-733
CrossRef173
Jack D. Sobel. (1997) PATHOGENESIS OF URINARY TRACT INFECTION. Infectious Disease Clinics of North America 11:3, 531-549
CrossRef174
Jill Kelly. (1997) Urinary Incontinence. Alternative and Complementary Therapies 3:4, 261-268
CrossRef175
D.H Barlow, G Samsioe, J.M van Geelen. (1997) A study of European womens' experience of the problems of urogenital ageing and its management. Maturitas 27:3, 239-247
CrossRef176
David T. Uehling, Walter J. Hopkins, Edward Balish, Yina Xing, Dennis M. Heisey. (1997) Vaginal Mucosal Immunization for Recurrent Urinary Tract Infection: Phase II Clinical Trial. The Journal of Urology 157:6, 2049-2052
CrossRef177
Tomas L. Griebling, Ingrid E. Nygaard. (1997) THE ROLE OF ESTROGEN REPLACEMENT THERAPY IN THE MANAGEMENT OF URINARY INCONTINENCE AND URINARY TRACT INFECTION IN POSTMENOPAUSAL WOMEN. Endocrinology & Metabolism Clinics of North America 26:2, 347-360
CrossRef178
Catherine D. Bacheller, Jack M. Bernstein. (1997) URINARY TRACT INFECTIONS. Medical Clinics of North America 81:3, 719-730
CrossRef179
D. Botsis, D. Kassanos, D. Kalogirou, G. Antoniou, P. Karakitsos, P.A. Zourlas. (1997) A comparative study of an estradiol-releasing vaginal ring versus tibolone in postmenopausal women: a transvaginal color Doppler study. Maturitas 27:1, 77-83
CrossRef180
Ronald, Allan, . (1996) Sex and Urinary Tract Infections. New England Journal of Medicine 335:7, 511-512
Full Text181
Gregor Reid, Jacqueline A. McGroarty, Lisa Tomeczek, Andrew W. Bruce. (1996) Identification and plasmid profiles of Lactobacillus species from the vagina of 100 healthy women. FEMS Immunology & Medical Microbiology 15:1, 23-26
CrossRef182
Gian Benedetto Melis, Angelo Cagnacci, Vincenzina Bruni, Leopoldo Falsetti, Valerio Maria Jasonni, Carmine Nappi, Franco Polatti, Annibale Volpe. (1996) Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause. Maturitas 24:1-2, 83-90
CrossRef183
Christer Johansson, Ulla Molander, Ian Milsom, Peter Ekelund. (1996) Association between urinary incontinence and urinary tract infections, and fractures in postmenopausal women. Maturitas 23:3, 265-271
CrossRef184
R. P. Schellart, W. R. Schouten, F. J. M. Huikeshoven. (1996) Anorectal manometry before, during and after estrogen replacement therapy. International Urogynecology Journal and Pelvic Floor Dysfunction 7:2, 77-80
CrossRef185
Jean Coope. (1996) Hormonal and non-hormonal interventions for menopausal symptoms. Maturitas 23:2, 159-168
CrossRef186
Stacy J. Childs, Robert J. Egan. (1996) BACTERIURIA AND URINARY INFECTIONS IN THE ELDERLY. Urologic Clinics of North America 23:1, 43-54
CrossRef187
Neil M. Resnick. (1996) GERIATRIC INCONTINENCE. Urologic Clinics of North America 23:1, 55-74
CrossRef188
Morris Notelovitz. (1995) Estrogen therapy in the management of problems associated with urogenital ageing: A simple diagnostic test and the effect of the route of hormone administration. Maturitas 22, S31-S33
CrossRef189
Gregor Reid, AndrewW. Bruce. (1995) Low vaginal pH and urinary-tract infection. The Lancet 346:8991-8992, 1704
CrossRef190
John-Gunnar Forsberg. (1995) A morphologist's approach to the vagina — age-related changes and estrogen sensitivity. Maturitas 22, S7-S15
CrossRef191
P. Riss. (1995) Gynäkologische Aspekte zum Harnwegsinfekt der Frau. Archives of Gynecology and Obstetrics 257:1-4, 651-653
CrossRef192
G Vooijs. (1995) Review of the endometrial safety during intravaginal treatment with estriol. European Journal of Obstetrics & Gynecology and Reproductive Biology 62:1, 101-106
CrossRef193
S. Keay, R.S. Schwalbe, A.L. Trifillis, J.C. Lovchik, S. Jacobs, J.W. Warren. (1995) A prospective study of microorganisms in urine and bladder biopsies from interstitial cystitis patients and controls. Urology 45:2, 223-229
CrossRef194
Ross R. Bailey. (1994) Management of uncomplicated urinary tract infections. International Journal of Antimicrobial Agents 4:2, 95-100
CrossRef195
G.K.M. Harding, A.R. Ronald. (1994) The management of urinary infections; what have we learned in the past decade?. International Journal of Antimicrobial Agents 4:2, 83-88
CrossRef196
E.R. te Velde, H.A.I.M. van Leusden. (1994) Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. The Lancet 343:8898, 654-658
CrossRef197
Desforges, Jane F., , Stamm, Walter E.Hooton, Thomas M.. (1993) Management of Urinary Tract Infections in Adults. New England Journal of Medicine 329:18, 1328-1334
Full Text198
Svanborg, Catharina, . (1993) Resistance to Urinary Tract Infection. New England Journal of Medicine 329:11, 802-803
Full Text
